Holen Sie sich die Stockscreener-App
20.96
3.51%
0.71
Handel nachbörslich:
21.18
0.22
+1.05%
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
Adaptive Biotechnologies Corp. Actuals & Estimates (TRADEGATE:1HM) - TradingView
BTIG Maintains a Buy Rating on Adaptive Biotechnologies (ADPT) - Insider Monkey
Adaptive Biotechnologies Corp. Actuals & Estimates (NASDAQ:ADPT) - TradingView
1HM Forecast — Price Target — Prediction for 2027 - TradingView
Adaptive Biotechnologies stock hits 52-week high at 20.82 USD By Investing.com - Investing.com Australia
Form 144 ADAPTIVE BIOTECHNOLOGIES CORPORATION For: 26 June By Investing.com - Investing.com Australia
[144] Adaptive Biotechnologies Corp SEC Filing - Stock Titan
Adaptive Biotechnologies stock hits 52-week high at 20.82 USD - Investing.com
Adaptive Biotechnologies Corp. Actuals & Estimates (FWB:1HM) - TradingView
Adaptive Biotechnologies CorpIssues $345 Million In 0% Convertible Senior Notes Due 2031SEC Filing - TradingView
Form 8K Adaptive Biotechnologies Corp For: 22 June By Investing.com - Investing.com South Africa
Adaptive Biotechnologies Prices $345 Million 0% Convertible Notes Due 2031, Adds Capped Call - TradingView
Adaptive Biotechnologies (Nasdaq: ADPT) sells $345M 0% notes and repays OrbiMed deal - Stock Titan
Adaptive Biotechnologies Corp (ADPT) Institutional Confidence - TradingKey
Insider Sell: Harlan Robins Sells 106,160 Shares of Adaptive Bio - GuruFocus
Adaptive Biotechnologies Corp (ADPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Adaptive Biotechnologies Corp (ADPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Adaptive Biotechnologies Corp (ADPT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Adaptive Biotechnologies CSO Harlan Robins sells $1.8m in stock - Investing.com UK
Adaptive Biotechnologies Corp (ADPT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Adaptive Biotechnologies Corp (ADPT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Adaptive Biotechnologies CSO Harlan Robins sells $1.8m in stock By Investing.com - Investing.com India
Adaptive Biotechnologies (ADPT) CSO sells 106K shares under 10b5-1 plan - Stock Titan
ADPT Reiterated by BTIG -- Price Target Maintained at $22 - GuruFocus
Adaptive Biotechnologies Business Separation May Unlock Greater Value - Benzinga
BTIG reiterates Adeptus Biotechnologies stock rating on business split By Investing.com - Investing.com South Africa
Analysts Are Bullish on Top Healthcare Stocks: Pasithea Therapeutics Corp (KTTA), Adaptive Biotechnologies (ADPT) - The Globe and Mail
Adaptive Biotechnologies Corp (ADPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Adaptive Biotechnologies Corp (ADPT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering - The Manila Times
Adaptive Biotechnologies Announces Pricing of $300 Million Convertible Senior Notes Offering to Enhance Financial Flexibility - Quiver Quantitative
Adaptive Biotechnologies raises $300M zero-interest debt, buys back stock - Stock Titan
Seattle biotech looks to raise up to $288 million amid plans to spin out immune medicine business - The Business Journals
Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses - Benzinga
Stock Market Today: S&P 500, Nasdaq Futures Fall, Dow Gains Amid US-Iran Deal— SpaceX, Dave And Buster's, Western Digital In Focus (UPDATED) - Benzinga
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering - The Manila Times
Adaptive Biotechnologies chief commercial officer sells $95,000 in shares - Investing.com UK
Adaptive Biotechnologies stock falls on convertible debt plan - Investing.com
Adaptive Biotechnologies chief commercial officer sells $95,000 in shares By Investing.com - Investing.com Nigeria
Executive at Adaptive Biotechnologies (ADPT) sells 5,000 shares under 10b5-1 plan - Stock Titan
Adaptive Biotechnologies plans $250M convertible notes offering By Investing.com - Investing.com Australia
Adaptive Biotechnologies plans to separate MRD, Immune Medicine units - Investing.com
Adaptive Biotechnologies plans $250M convertible notes offering - Investing.com
Adaptive Biotechnologies stock falls on convertible debt plan By Investing.com - Investing.com India
Adaptive Biotechnologies proposes $250M convertible notes, plans MRD/Immune Medicine separation - TradingView
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses - The Manila Times
Adaptive Biotechnologies (NASDAQ: ADPT) to sell $250M converts and explore MRD–Immune Medicine split - Stock Titan
Adaptive Biotechnologies plans split: MRD tests vs AI immune unit - Stock Titan
Adaptive Biotechnologies lines up $250M note deal to repay debt, buy back shares - Stock Titan
Kennedy Capital Management LLC Trims Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
1.76%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):